

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal

Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791 and TA991) [ID6689]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Accord (denosumab, ibandronic acid, teriparatide) • Amgen (denosumab) • Aspire Pharma (ibandronic acid, raloxifene, risedronate sodium) • Atnahs Pharma (ibandronic acid) • Aurobindo Pharma - Milpharm (alendronic acid, risedronate sodium) • Bowmed Ibisqus (zoledronic acid) • Celltrion Healthcare UK (denosumab) • Dr. Reddy's Laboratories (denosumab, zoledronic acid) • Eli Lilly (teriparatide) • Ennogen IP (zoledronic acid) • Fresenius Karbi (denosumab, zoledronic acid) • Gedeon Richter (denosumab, teriparatide) • Genus Pharmaceuticals (denosumab) • Internis Pharmaceuticals (alendronic acid) • MAbxience Research (denosumab) • Martindale Pharma, an Ethypharm Group Company (zoledronic acid) • Morningside Healthcare (zoledronic acid) • Organon Pharma (alendronic acid, denosumab) • Phoenix Labs (zoledronic acid) • Rosemont (alendronic acid) • Samsung Bioepis UK (denosumab) • Sandoz (alendronic acid, denosumab, ibandronic acid, risedronate sodium, zoledronic acid) 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • NHS Wales Joint Commissioning Committee • Scottish Medicines Consortium • Welsh Government <p><u>Comparator companies</u> Not applicable</p> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • Chronic Pain Policy Coalition • Cochrane Bone, Joint and Muscle Trauma Group • Cochrane Gynaecology and Fertility Group • Cochrane Metabolic & Endocrine Disorders Group • Cochrane Musculoskeletal Group • Cochrane UK • Genomics England

Final stakeholder list for the evaluation of medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791 and TA991) [ID6689]

Issue date: June 2026

© National Institute for Health and Care Excellence 2026. All rights reserved.

Page 1 of 4

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Seacross Pharmaceuticals (zoledronic acid) • Sovereign Medical (risedronate sodium) • Sun Pharmaceutical Company (teriparatide, zoledronic acid) • Teva UK (denosumab, teriparatide) • Theramex (abaloparatide) • Thornton & Ross (teriparatide) • Tillomed Laboratories (zoledronic acid) • UCB Pharma (romosozumab) • Unicorn Pharmaceuticals (zoledronic acid) • Viatrix (alendronic acid, zoledronic acid) • Zentiva (denosumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Arthritis Action • Arthritis and Musculoskeletal Alliance • Arthritis UK • Arthritis and Musculoskeletal Alliance • Back Care • BAME Health Collaborative Charity • Black Health Agency for Equality • Daisy Network • Menopause Exchange • Menopause Matters • Menopause UK • Pain Concern • Pain Relief Foundation • Pain UK • Pregnancy Associated osteoporosis UK • Queer Menopause • Royal Osteoporosis Society • South Asian Health Foundation • Specialised Healthcare Alliance • The Menopause Charity • Women’s Health Concern <p><u>Healthcare professional groups</u></p>	<ul style="list-style-type: none"> • MRC Clinical Trials Unit • National Institute of Health and Care Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

Final stakeholder list for the evaluation of medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791 and TA991) [ID6689]

Issue date: June 2026

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Dietetic Association • British Geriatrics Society • British Institute of Radiology • British Menopause Society • British Orthopaedic Association • British Pain Society • British Society for Rheumatology • British Society of Physical and Rehabilitation Medicine • National Osteoporosis Guideline Group • Physiotherapy Pain Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and the College of Radiographers • Society for Endocrinology • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • Health Technology Wales (HTW) • NHS England 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.